Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
about
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.The prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel.Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistanceMedical management of metastatic prostate cancer
P2860
Q48107095-6676F1A7-977E-476C-B4B4-278B79B6B63FQ48272997-EFC29A79-7E73-4FF2-9E2E-C6EB29811351Q51746022-4B272DDB-05AB-431F-A868-E508785597F8Q52676556-648737D8-9421-4571-BFC6-F142BFEC311EQ53822455-94A116AA-1E04-4D63-9850-81E095D75387Q58547123-D7E82287-118E-4B3C-96A8-107CC338A9ECQ58588895-333BF1F8-E7C9-4A89-B14D-A9F3E18A946E
P2860
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Phase III Study Comparing a Re ...... ant Prostate Cancer-PROSELICA.
@en
type
label
Phase III Study Comparing a Re ...... ant Prostate Cancer-PROSELICA.
@en
prefLabel
Phase III Study Comparing a Re ...... ant Prostate Cancer-PROSELICA.
@en
P2093
P356
P1476
Phase III Study Comparing a Re ...... ant Prostate Cancer-PROSELICA.
@en
P2093
Albert Font
Anne-Claire Hardy-Bessard
Choung Soo Kim
Daniel Ford
Gabriel Kacso
Joan Carles
Johann de Bono
John Bernard
Lajos Géczi
Loïc Mourey
P304
JCO2016721076
P356
10.1200/JCO.2016.72.1076
P407
P577
2017-08-15T00:00:00Z